In this episode, 'Screening, Risk Stratification, and the Multidisciplinary Care Model for MASH,' the hepatologist Nadege Gunn, MD explores the following questions: 1. How would you characterize the ...

Indications now include pediatric plaque psoriasis and active PsA starting at age 6, positioning risankizumab as the first US-approved IL-23(p19) inhibitor for <40 kg pediatric patients. Weight-tiered ...

A $5,000 annual out-of-pocket cap would add catastrophic financial protection to traditional Medicare, harmonizing benefit design with Medicare Advantage and most private insurance coverage.

Wastewater signals suggest increasing SARS-CoV-2 circulation despite low national baselines, reinforcing surveillance as an early indicator rather than a definitive predictor of near-term clinical ...

COA’s AI Playbook provides a structured, practice-oriented framework to prioritize AI use cases, align stakeholders, and ...

Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...

Delgocitinib tripled week-16 treatment success versus placebo (RR 3.17), yielding an absolute 16.9% benefit and NNT of 6. Early separation by week 4 supports adherence, with sustained superiority at ...

Learn how aggressive neuroendocrine carcinoma disrupts daily life—and why rapid treatment, strong caregiver support, and navigation resources matter. In this episode, ‘Current Treatments and Biomarker ...

CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...

AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

Life sciences executives are entering the second half of 2026 with a split view of their industry: deep unease about the ...